Clinical trials: Cholesterol; Metabolic Disorder
Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2
ScreenPlus: A Comprehensive, Flexible, Multi-disorder Newborn Screening Program
ScreenPlus is a consented, multi-disorder pilot newborn screening program implemented in conjunction with the New York State Newborn Screening Program that provides families the option to have their newborn(s) screened for a…
- Conditions
- Acid Sphingomyelinase Deficiency, Ceroid Lipofuscinosis, Neuronal, 2, Cerebrotendinous Xanthomatosis, Fabry Disease
- Trial name
- ScreenPlus (NCT05368038)
- Testing
- Confirmatory Testing
- Where
- 9 sites in United States
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Albert Einstein College of Medicine
Hypercholesterolemia, Coronary Heart Disease
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
This is a multicenter, randomized, parallel group, placebo controlled study designed to evaluate the efficacy, safety, and tolerability of ezetimibe added to ongoing atorvastatin therapy compared with ongoing atorvastatin…
- Trial name
- NCT00202904
- Testing
- ezetimibe
- Volunteers
- 81 people
- Sponsor
- Organon and Co
Dyslipidemias, Lipid Disorder
Assessment of Different Equations to Accurately Calculate LDL Cholesterol
Purpose The LDL-C is a very important marker of the lipid panel which allows the introduction of a treatment and then the follow-up to prevent the cardiovascular risk.
- Trial name
- LDL FORMULA (NCT05598216)
- Testing
- no intervention, Serum LDL cholesterol calculation
- Where
- France
- Volunteers
- 160,000 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Hyperlipidemia, Cardiovascular Disease
Portfolio 5 - Multicentre Dietary Advice on Serum Lipids in Hyperlipidemia
The purpose of this trial is to re-evaluate the potential role of diet in modulating cardiovascular risk factors. If potent lipid-lowering effects through novel dietary interventions can be demonstrated, then diet may again be…
- Trial name
- NCT00438425
- Testing
- Dietary Portfolio - Intensive, Dietary Portfolio - Routine, Control (low saturated fat therapeutic diet)
- Where
- 5 sites in Canada
- Volunteers
- 351 people
- Sponsor
- University of Toronto
Diabetes Mellitus Type 2, Crestor, Rosuvastatin
DIALOOG: Crestor in Patients With Diabetes Mellitus Type 2: Lowering of LDL-C Levels to New European Guidelines
The purpose of this study is to determine in DM II patients the efficacy of Crestor in obtaining the new European LDL cholesterol guidelines.
- Conditions
- Diabetes Mellitus Type 2, Crestor, Rosuvastatin, LDL Cholesterol, Observational
- Trial name
- NCT00233649
- Where
- 222 sites in Netherlands
- Volunteers
- 2,500 people
- Sponsor
- AstraZeneca
Dyslipidemia, Hypercholesterolemia
A Dose-Finding Study in Japanese Patients to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy.
This study will be a placebo-controlled, double-blind, randomized, phase 2 dose-finding study in Japanese patients to evaluate the efficacy, safety, and tolerability of obicetrapib as an adjunct to stable statin therapy.
- Conditions
- Dyslipidemia, Hypercholesterolemia, High Cholesterol
- Trial name
- NCT05421078
- Testing
- Obicetrapib
- Where
- 10 sites in Japan
- Volunteers
- 102 people
- Sponsor
- NewAmsterdam Pharma
Overweight, Children
Prevention of Excessive Weight Gain by Discouraging Students From Drinking Sodas
The purpose of this study was to encourage students to reduce soft drinks intake, substituting it by water, in order to prevent and control overweight prevalence.
- Trial name
- NCT02653352
- Testing
- Lifestyle modification
- Volunteers
- 1,140 people, healthy volunteers welcome
- Sponsor
- Rio de Janeiro State University
Hypercholesterolemia
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
To investigate the effect of rosuvastatin compared to placebo on the aortic stiffness in hemodialysis patients as measured by pulse wave velocity (at 3, 6 and 12 months)
- Trial name
- NCT00240279
- Testing
- Rosuvastatin, aortic pulse wave velocity measurements
- Where
- Netherlands
- Volunteers
- 10 people
- Sponsor
- AstraZeneca
Hypercholesterolemia, Osteoporosis
Effect of β-cryptoxanthin (β-Cx), Plant Sterols and Galactooligosaccharides on Systemic and Gastrointestinal Markers
Regular consumption of a beverage containing β-cryptoxanthin (β-Cx) and plant sterols (PS) has been shown to exert a synergic effect in reducing some markers of cardiovascular risk and bone-remodeling (formation and resorption).
- Conditions
- Hypercholesterolemia, Osteoporosis, Postmenopausal Disorder
- Trial name
- NCT03469518
- Testing
- β-Cx plus PS plus GOS, β-Cx plus PS
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Puerta de Hierro University Hospital
Cardiovascular Risk Factor, Pre Diabetes
Effects of a Workplace Exercise Intervention on Cardio-Metabolic Health
Background: The rising levels of physical inactivity in the Eastern Mediterranean region (43.2%) and in the United Arab Emirates (38%) compared with the global levels of physical inactivity (31.2%) is alarming (6,15).
- Conditions
- Cardiovascular Risk Factor, Pre Diabetes, High Blood Pressure, Elevated LDL Cholesterol
- Trial name
- NCT04403789
- Testing
- Exercise Time, Supervised Group Exercise
- Where
- United Arab Emirates
- Volunteers
- 130 people, healthy volunteers welcome
- Sponsor
- United Arab Emirates University
Hyper-LDL-cholesterolemia, Metabolic Syndrome
The Effects of Strawberries on Blood Cholesterol.
In this study, we propose to investigate the effects of dietary achievable doses of strawberries on serum LDL-cholesterol (LDL-C) and related lipid profiles, measures of glycemia and insulin resistance, and biomarkers of…
- Trial name
- NCT03441620
- Testing
- strawberries, Control powder
- Where
- 3 sites in United States
- Volunteers
- 33 people
- Sponsor
- University of Nevada, Las Vegas
Primary Hypercholesterolemia, Mixed Dyslipidemia
Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With High Cholesterol or Abnormal Lipid Levels (MK-0524A-133)
This is a multicenter, randomized, double-blind, placebo-controlled study in participants with primary hypercholesterolemia or mixed dyslipidemia, and elevated low density lipoprotein-cholesterol (LDL-C) to assess the efficacy…
- Trial name
- NCT01274559
- Testing
- Extended-release niacin/laropiprant (ERN/LRPT)
- Volunteers
- 1,173 people
- Sponsor
- Merck Sharp & Dohme LLC
Hypercholesterolemia, Atherosclerotic Cardiovascular Disease (ASCVD)
Dual PCSK9 Inhibition With Inclisiran and Alirocumab in Secondary Prevention
This study will evaluate the effectiveness and safety of combining two different types of PCSK9 inhibitors, inclisiran and alirocumab, in patients with high cardiovascular risk who are unable to tolerate statins.
- Trial name
- PCSK9-DUO (NCT07581808)
- Testing
- Inclisiran, Alirocumab
- Where
- Slovenia
- Volunteers
- 60 people
- Sponsor
- University Medical Centre Ljubljana
Hyperlipidemia
Effect of Butter & MCT Oil on Lipoproteins - A RCT
Determine the effects on lipoprotein profiles of high dose concentrated dietary SFA (saturated fatty acids) (from MCT (medium-chain triglyceride) oil + butter) in combination added to coffee.
- Trial name
- NCT02611102
- Testing
- MCT oil + Butter in Coffee
- Where
- United States
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Walter Reed National Military Medical Center
Dyslipidemia
Effect of Lapaquistat Acetate on Blood Cholesterol Levels in Subjects With Elevated Cholesterol
The purpose of this study is to determine if patients with elevated cholesterol, but not taking any other lipid medication, could lower their cholesterol with administration of lapaquistat acetate, once daily (QD).
- Trial name
- NCT00143663
- Testing
- Lapaquistat Acetate
- Where
- 47 sites in United States
- Volunteers
- 361 people
- Sponsor
- Takeda
Rheumatoid Arthritis
Effects Of CP-690,550 (Tasocitinib) On Cholesterol Metabolism In Patients With Active Rheumatoid Arthritis
The purpose of study is to explore the effect of CP-690,550 (tasocitinib) on cholesterol metabolism in patients with active rheumatoid arthritis (RA).
- Trial name
- NCT01262118
- Testing
- CP-690,550 (tasocitinib)
- Where
- 11 sites in United States, Hungary
- Volunteers
- 69 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pregnancy, Gestational Diabetes
Behavior of Biomarkers During Pregnancy and Lactation Through a Biological Multi-paradigm Model: BECOME Study Protocol
Background Despite of advances in research, at the moment, various points related to the physiology of gestation and the etiology of severe diseases that can be developed in the course of it remain unknown.
- Conditions
- Pregnancy, Gestational Diabetes, Hypertension, Obesity
- Trial name
- BECOME (NCT02811172)
- Testing
- BEhavior of biomarkers during pregnanCy and lactatiOn
- Where
- Spain
- Volunteers
- 224 people, healthy volunteers welcome
- Sponsor
- Universidad de Granada
Hypercholesterolemia
A Study of LY3015014 in Participants With High Cholesterol
This study is designed to define the amount and duration of cholesterol lowering and to assess the safety and tolerability of different dose regimens of LY3015014 in participants with high cholesterol.
- Trial name
- NCT01890967
- Testing
- LY3015014, Statin, Ezetimibe
- Where
- 49 sites in United States, Canada and 6 more
- Volunteers
- 527 people
- Sponsor
- Eli Lilly and Company
Primary Hyperlipidemia and Mixed Dyslipidemia
Effects on Lipoprotein Metabolism From PCSK9 Inhibition Utilizing a Monoclonal Antibody
This is a randomized, double-blind, placebo-controlled trial to evaluate the effect of evolocumab, atorvastatin, and combination therapy on lipoprotein kinetics.
- Trial name
- FLOREY (NCT02189837)
- Testing
- Evolocumab, Atorvastatin
- Where
- 2 sites in Australia
- Volunteers
- 89 people, healthy volunteers welcome
- Sponsor
- Amgen
Dyslipidemias, Atherosclerotic Cardiovascular Disease
Tracking of Lipid Lowering Therapy in Jordan
The present study aims to examine the clinical practice of modifying the dose of lipid-lowering therapy in patients with atherosclerotic cardiovascular disease (ASCVD), who have LDL-C > 70 mg/dl despite statin treatment.
- Trial name
- JoLLA (NCT05629767)
- Where
- 2 sites in Jordan
- Volunteers
- 1,000 people
- Sponsor
- Jordan Collaborating Cardiology Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.